The skin fluorescent imaging (SFI) system offers non-invasive molecular testing for difficult-to-characterize moles, potentially reducing unnecessary biopsies.
2
SFI identifies biological tissue remodeling associated with melanoma, providing molecular information that enhances decision-making in lesion assessment.
3
In a study of 251 subjects, SFI demonstrated 100% detection of oncogenic activity in melanoma cases, indicating high likelihood for melanoma development.
4
The SFI system achieved an AUC of 0.907, indicating solid discriminatory performance in distinguishing lesions undergoing melanoma-related remodeling.
5
SFI complements dermoscopy by providing non-invasive biological information, improving the accuracy of lesion evaluations and biopsy decisions.
Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.
